“Sales in the first quarter of 2026 reached USD 232 million, representing reported growth of 15% and organic growth of 4%. We delivered strong performance in Prosthetics & Neuro Orthotics, driven by continued momentum and solid volume growth across regions and categories.

EBITDA margin was 17%, reflecting the impact of external factors such as FX and tariffs. We continue to execute with discipline and remain focused on delivering margin expansion as growth accelerates."

Embla hosted a conference call for Interim Report Q1 2026 on April 28, 2026.

A recording of this presentation can be viewed via the link below:

Embla Medical Q1 2026 Webcast (Transcript)

Related documents:

• Company Announcement (PDF)
• Investor Presentation (PDF)